Further research is needed to find out whether TPMT genetic polymorphisms are responsible for leukopenia in CD patients and whether thiopurines undergo different enzymatic modifications giving rise to active and inactive metabolites that influence their therapeutic effects differently in IBD patients. The gene discussed is TPMT; the disease is inflammatory bowel disease.